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Abstract
Aims/hypothesis There are potential advantages to the low-
temperature (−196°C) banking of isolated islets, including
the maintenance of viable islets for future research. We there-
fore assessed the in vitro and in vivo function of islets cryo-
preserved for nearly 20 years.
Methods Human islets were cryopreserved from 1991 to 2001
and thawed between 2012 and 2014. These were characterised
by immunostaining, patch-clamp electrophysiology, insulin
secretion, transcriptome analysis and transplantation into a
streptozotocin (STZ)-induced mouse model of diabetes.
Results The cryopreservation timewas 17.6±0.4 years (n=43).
The thawed islets stained positive with dithizone, contained
insulin-positive and glucagon-positive cells, and displayed
levels of apoptosis and transcriptome profiles similar to those
of freshly isolated islets, although their insulin content was
lower. The cryopreserved beta cells possessed ion channels
and exocytotic responses identical to those of freshly isolated
beta cells. Cells from a subset of five donors demonstrated
similar perifusion insulin secretion profiles pre- and post-cryo-
preservation. The transplantation of cryopreserved islets into
the diabetic mice improved their glucose tolerance but did not
completely normalise their blood glucose levels. Circulating
human insulin and insulin-positive grafts were detectable at
10 weeks post-transplantation.
Conclusions/interpretation We have demonstrated the poten-
tial for long-term banking of human islets for research, which
could enable the use of tissue from a large number of donors
with future technologies to gain new insight into diabetes.
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Introduction
The ability to preserve human islets for an extended period of
time has several benefits. These may include increasing the
practicality of islet transplantation for type 1 diabetes by im-
proving the prospects for pre-transplant testing, simultaneous
multiple donor transplants and simplified logistics. However,
human islets are increasingly being recognised as a valuable
research resource [1], and concerns have been raised about the
future of access to human research islets [2]. Biobanking is
one way to address this and to facilitate the progress of re-
search into the mechanisms underlying diabetes. However, the
successful storage of functional islets has not been achieved
beyond 2 years—far too short a time for successful long-term
biobanking.
Culturing islets extends their viable lifespan to a certain
degree, but long-term maintenance of the phenotype has
proved problematic [3, 4]. Schmied et al have reported the
maintenance of endocrine cells to be limited to 60 days, with
hormone secretion lost by day 28 [5], although Fraga et al
observed glucose-stimulated insulin secretion following
2 months of culture [6]. The cryopreservation of islets has
been considered to be a potential tool since the first demon-
strations of the reversal of hyperglycaemia by frozen-thawed
islets in rats used as a model of streptozotocin (STZ)-induced
diabetes [7, 8]. Cryopreservation was initially undertaken with
rodent and canine islets, and the cryopreservation of human
islets was first reported in 1980 [9]. Using a protocol we had
developed by 1989 [10, 11], we obtained reasonable results
using islets cryopreserved for an average of 44 days, in which
the insulin secretory responses were 79% of the pre-freezing
levels [12]. The transplantation of a mixture of fresh and cryo-
preserved islets into patients with type 1 diabetes receiving
kidney transplants demonstrated long-term graft function,
with one patient becoming independent of insulin for 2.5 years
[13, 14].
In the past 10 years, new cryopreservation protocols have
been developed in an attempt to improve islet viability after
thawing. These include pre- and post-culture with
astragalosides, Sertoli cells, ductal epithelia, antioxidants and
P38 MAP kinase (MAPK) inhibition [15–19]. Numerous
cryoprotectants, including silk protein, DMSO, hydroxyethyl
starch, glycerol and synthetic glycoprotein, have been inves-
tigated [20–23]. More recently, there has been a report of an
increased duration of cryopreservation (3 months) and an as-
sessment of post-thawing status including gene expression
profiling, viability, insulin secretion and in vivo engraftment
[24]. In addition, Misler et al have investigated the electro-
physiological and secretory responses of islets following cryo-
preservation for up to 2 years [25].
Although the cryopreservation of human islets would be
beneficial in enabling their future use, a true long-term bank-
ing of functional islets has not been reported. The University
of Alberta is exceptional in terms of its large biobank of cryo-
preserved human islets [26]. Despite their success in clinical
trials [13, 27], these frozen islets have, however, been deemed
to be unsuitable for transplantation using the Edmonton pro-
tocol [28] owing to the presence of FBS. As such, preparations
for which the donors had given research consent were desig-
nated as research islets. Here we assess the function of human
islets obtained from this facility following cryopreservation
for up to 21 years and demonstrate the potential for this ap-
proach to provide a source of high-quality, viable research
tissue.
Methods
Human islets We thawed and examined cryopreserved islet
preparations from 43 human donors. These had been cryo-
preserved using the method developed by Rajotte et al
[11] with DMSO as a cryoprotectant and had been stored
under liquid-phase N2 for 17.6±0.4 years. The mean age
of the donors was 40.9±2.0 years, with 47% male vs 53%
female donors. Freshly isolated islets were obtained from
the Alberta Diabetes Institute IsletCore and the Clinical
Islet Laboratory at the University of Alberta. The mean
age of the donors of these was 60.5±3.0 years, with
56% male vs 43% female donors. All the studies were
approved by the Human Research Ethics Board at the
University of Alberta.
Human islet culture Cryopreserved islet preparations were
thawed by rapid (150°C/min) warming to 4°C followed by the
removal of DMSO with a sucrose gradient and serial dilution
of cryoprotectant [11]. The islets were subsequently cultured
overnight in CMRL 1066 (Corning, Tewksbury, MA, USA)
supplemented with 0.5% BSA (Equitech-Bio, Kerrville,
TX, USA), 1% Insulin-Transferrin-Selenium (Corning),
100 U/mL penicillin/streptomycin (Life Technologies,
Burlington, ON, Canada) and L-glutamine (Sigma-Aldrich,
Oakville, ON, Canada). Both the cryopreserved and the fresh-
ly isolated islets were cultured for an additional 24 h in low-
glucose (1 g/L) DMEM supplemented with 10% FBS and
100 U/mL penicillin/streptomycin.
Transcriptome analysis Thawed islets (n=32 donors) or
freshly isolated islets (n=18 donors) were hand-picked and
RNAwas extracted using Trizol reagent (Life Technologies).
RNA sequencing was performed on an Illumina HiSeq 2000
(Illumina, San Diego, CA, USA) with 100 bp paired-end se-
quencing. Libraries were prepared using the NEBNext Ultra
Directional RNA Library Prep Kit for Illumina (New England
BioLabs, Hitchin, UK) with custom 8 bp indexes [29]. The
TruSeq PE Cluster Kit v3 (Illumina) was used for cluster gen-
eration and the TruSeq SBS Kit v3 (Illumina) for sequencing.
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Sequenced reads were mapped to the human genome
(GRCh37) with Tophat v2.0.12 (www.ccb.jhu.edu/software/
tophat/index.shtml) [30] using Gencode v18 (www.
gencodegenes.org) as the transcriptome reference.
Expression was quantified using Cuffquant and Cuffnorm
(http://cole-trapnell-lab.github.io/cufflinks/) [30] on default
settings.
Immunohistochemistry and TUNEL staining Islets and is-
let grafts were fixed in Z-fix (Anatech, Battle Creek, MI,
USA), embedded in paraffin and sliced into 5 μm sections.
Immunostaining for insulin (Santa Cruz Biotechnology,
Dallas TX, USA; or DAKO Canada, Burlington, ON,
Canada) and glucagon (EMD Millipore, Billerica, MA,
USA) was performed as previously described [31].
Apoptosis was assessed by in situ TUNEL (Roche
Diagnostics, Laval, QC, Canada) according to the manufac-
turer’s instructions. Slides were coverslipped with prolong
gold antifade with DAPI, visualised with an Axioscope II with
AxioCamMRC and analysed using Axiovision 4.6 (Carl
Zeiss, Gottingen, Germany).
Electrophysiology The islets were dispersed by shaking in
dissociation buffer (Life Technologies) and plated in 35 mm
dishes. The standard whole-cell technique was used with the
sine+DC lock-in function of an EPC10 amplifier and
Patchmaster software (HEKA Electronik, Lambrecht/Pfalz,
Germany). Experiments were performed at 32–35°C. To mea-
sure the voltage-dependent K+ (Kv) currents, an intracellular
solution was used containing (in mmol/l): 140 KCl, 1 CaCl2, 1
MgCl2, 10 HEPES, 10 EGTA and 3 ATP-Mg (pH 7.3 with
KOH). The bath solution contained (in mmol/l): 135 NaCl,
5.4 KCl, 1 CaCl2, 1.2 MgCl2, 10 HEPES and 5 glucose (pH
7.3 with NaOH). To measure the capacitance, a bath solution
was used that contained (in mmol/l): 118 NaCl, 20
tetraethylammonium chloride, 5.6 KCl, 1.2 MgCl2·6H2O,
2.6 CaCl2, 1 or 10 glucose and 5 HEPES (pH 7.4 with
NaOH). The pipette solution for capacitance measurement
contained (in mmol/l): 125 Cs-glutamate, 10 CsCl, 10 NaCl,
1 MgCl2·6H2O, 0.05 EGTA, 5 HEPES, 0.1 cAMP and 3
MgATP (pH 7.15 with CsOH). The patch pipettes, pulled
from borosilicate glass and coated with Sylgard (World
Precision instruments, Sarasota, FL, USA), had resistances
of 3–4 MΩ when filled with pipette solution. The whole-cell
Kv current and capacitance responses were normalised to the
initial cell size and expressed as pA/pF and fF/pF, respective-
ly. The beta cells were positively identified after the experi-
ment by insulin immunostaining.
Insulin secretion Static insulin secretion measurements were
performed at 37°C in KRB (in mmol/l: 115 NaCl, 5 KCl, 24
NaHCO3, 2.5 CaCl2, 1 MgCl2, 10 HEPES and 0.1%BSA; pH
7.4). Twenty islets per group were pre-incubated for 2 h in
1 mmol/l glucose KRB. These were subsequently incubated
for 1 h in KRB with 1 mmol/l glucose, followed by 1 h with
16.7 mmol/l glucose and then 1 h with 16.7 mmol/l glucose
plus 20 mmol/l KCl. The islets were extracted with
acid/ethanol to determine their insulin content. The samples
were stored at −20°C and assayed for insulin using an
electrochemiluminescence assay (Meso Scale Discovery,
Rockville, MD, USA).
Insulin secretion was measured pre- and post-
cryopreservation in five donors by perifusion assay. Pre-
cryopreserved islets were perfused with Hanks’ Balanced
Salt Solution (containing 2.8 or 28 mmol/l glucose), and sam-
ples were collected and assayed for insulin using radioimmu-
noassay. Post-thaw insulin perifusions were performed using a
PERI-4.2 perifusion machine (Biorep Technologies, Miami,
FL, USA). Twenty islets per chamber were perfused with
KRB (containing 2.8 or 28 mmol/l glucose) at a flow rate of
250 μl/min with samples collected at 2 min intervals.
Islet transplantation Male B6.129S7-Rag1tm1Mom/J (B6/
Rag−/−) mice (Jackson Laboratory, Bar Harbor, ME, USA)
were rendered diabetic by the intraperitoneal injection of
streptozotocin (STZ; 185 mg/kg). Three days after the induc-
tion of diabetes, islets thawed after cryopreservation (2,000 or
4,000 islet equivalents [IEQ]) or freshly isolated islets (3,000
IEQ) were transplanted under the kidney capsules of the mice
[32]. Their body weight and blood glucose levels were mon-
itored over 10 weeks. Blood glucose and plasma insulin
(Meso Scale Discovery) were both measured in response to
an oral glucose load (3 mg/g body weight) pre- and post-ne-
phrectomy, which occurred at week 10. The islet graft was
extracted in acid-ethanol to determine the insulin content or
embedded and sectioned for immunohistochemistry. All mu-
rine experiments were approved by the Animal Care and Use
Committee at the University of Alberta.
Data analysis Data were analysed using FitMaster (HEKA
Electronik) and Origin 9.1 (OriginLab, Northampton, MA,
USA) and compared using multiple ANOVA and the
Student’s t test. Data are expressed as mean±SE, and
p<0.05 was considered significant.
Results
Human islets following long-term cryopreservation and
thawing Human islet preparations (n=43, frozen for 17.6±
0.4 years) were rapidly thawed using the method described by
Rajotte et al [11] to limit osmotic damage. The cells were
immediately stained with dithizone (Fig. 1a). Estimates of islet
purity pre- and post-cryopreservation were positively correlat-
ed (slope=0.84, r2=0.73, p<0.001; Fig. 1b), and cryopreser-
vation did not significantly decrease the purity (51.2±4.4 vs
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47.2±4.1%, n=41). Immunofluorescence staining revealed
the expression of both insulin-positive beta cells and
glucagon-positive alpha cells (Fig. 1c), which appeared to be
similar in their distribution to previous reports [33].
Apoptosis, assessed by TUNEL, did not differ between fresh-
ly isolated (9.4±1.2%, n=4 donors) and cryopreserved islets
(8.9±1.8%, n=5 donors; Fig. 1d, e) and was similar to values
previously reported [34–37].
Cryopreserved beta cells retain ion channel function and
exocytotic responsiveness A critical component of beta
cell function is the electrical activity mediated by the
ion channels, leading to Ca2+ influx and the exocytosis
of insulin-containing granules [38, 39]. Whole-cell patch-
clamp was used to assess the Kv current, a key regulator
of action potentials and insulin secretion [40, 41]. The
Kv currents from cryopreserved (n=15 donors, 45 cells)
and freshly isolated (n=3 donors, 15 cells) beta cells
identified by positive insulin immunostaining were simi-
lar (138.6±11.7 vs 130.3±11.3 pA/pF; Fig. 2a, b).
Voltage-dependent Ca2+ channels (VDCCs) underlie the
inf lux of Ca2+ on glucose-s t imulated membrane
depolarisation to trigger the release of insulin granules [41].
VDCC currents exhibited similar activity in cryopreserved
beta cells (−0.68±0.09 pC/pF, n=8 donors, 31 cells) and
freshly isolated beta cells (−0.50±0.07 pC/pF, n=6 donors,
24 cells; Fig. 2c, d). Although the beta cells from the cryopre-
served islets tended to show a larger Ca2+ entry in response to
depolarisation, this was not statistically significant.
The fusion of insulin granules with the cell membrane can
be measured as an increase in cell capacitance in response to a
train of depolarisations [42]. The magnitude of this response is




































































Fig. 1 Human islets following
long-term cryopreservation. (a)
Islets were stained with dithizone
immediately following isolation
or on thawing following long-
term cryopreservation. Scale bar,
1 mm. (b) Correlation of islet
purity estimates at isolation (Pre-
freeze) and after thawing (Post-
thaw). (c) Representative image
of a long-term cryopreserved
islet, immunostained for insulin
(green) and glucagon (red), with
nuclei stained with DAPI (blue).
Scale bar, 100 μm. (d)
Representative image of a freshly
isolated and a cryopreserved islet
stained for insulin (red), TUNEL
(green) and DAPI (blue). Scale
bar, 100 μm. (e) Percentage of
apoptotic (TUNEL-positive) cells
within freshly isolated islets from
four donors (grey circles) and
cryopreserved islets from five
donors after thawing (black
circles). Each circle represents a
separate image set (17,185 cells)
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sensitive to glucose level in healthy beta cells [43], probably
reflecting a metabolism-driven increase in insulin granule traf-
ficking or priming. The cryopreserved beta cells had intact
exocytotic responses and retained their sensitivity to glucose
(5.0±0.6 fF/pF at 1 mmol/l glucose vs 15.0±1.4 fF/pF at
10 mmol/l glucose, n=9 donors, 46–70 cells), which was sim-
ilar to that seen in healthy, freshly isolated beta cells (4.1±
0.9 fF/pF at 1 mmol/l glucose vs 17.0±2.2 fF/pF at 10 mmol/l
glucose, n=6 donors, 20–26 cells; Fig. 2e, f).
Cryopreserved human islets exhibit glucose-stimulated
insulin secretion Our electrophysiological studies indicated
that the ion channels and exocytotic machinery necessary to
elicit insulin granule fusion remained intact following cryo-
preservation. We were able to directly compare the secretory
profile of the islets from five donors before cryopreservation
(Fig. 3a) and then after thawing almost 20 years later (Fig. 3b).
Glucose-stimulated (28 mmol/l) secretion was remarkably
similar in magnitude both pre- and post-cryopreservation,
with a modest difference in the profile that was likely to be
attributable to improved methodology or increased sampling
frequency.
The secretion of insulin from the islets was measured
following static incubation with 1mmol/l glucose, 16.7mmol/
l glucose or 16.7mmol/l glucose plus 20mmol/l KCl. Glucose

























































































Fig. 2 Single cell function is maintained in long-term cryopreserved
human beta cells. (a, b) Representative Kv currents and current–voltage
relationships from freshly isolated (white circles) and long-term cryopre-
served (black circles) human beta cells. (c, d) Representative VDCCs and
Ca2+-charge entry during depolarisation in freshly isolated (white bar)
and long-term cryopreserved (black bar) human beta cells. (e, f) Repre-
sentative exocytotic responses, shown as increases in membrane capaci-
tance (i.e. surface area) in response to a series of membrane
depolarisations, and summarised data from freshly isolated (white sym-
bols) and long-term cryopreserved (black symbols) human beta cells in
response to 1 mmol/l (squares) and 10 mmol/l (circles) glucose. In all

























































































































































Fig. 3 Function of intact cryopreserved human islets in vitro. (a, b)
Insulin secretion measured by perifusion in response to 28 mmol/l glu-
cose (high glucose) from islets following isolation (a) and then from the
same preparations after thawing approximately 20 years later (b). (c, d)
Static insulin secretory responses of long-term cryopreserved islets to
16.7 mmol/l glucose alone (c) or with 20 mmol/l KCl (d). (e, f) The
secretory responses to KCl and glucose were positively correlated (e),
but secretory competence did not correlate with the duration of cryopres-
ervation (f). (g) Transcriptome analysis demonstrated a high degree of
correlation of transcript expression between cryopreserved and freshly
isolated islets (Spearman’s ρ=0.94). The expression level of several beta
cell function genes is indicated. FPKM, fragments per kilobase of exon
per million fragments mapped; SI, stimulation index
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and KCl stimulated insulin secretion with stimulation indices
of 1.90±0.24 and 1.96±0.24, respectively (n=41–43 donors).
The stimulation of insulin secretion in response to glucose (n=
43) and KCl (n=41) reached statistical significance (at
p<0.05) for 37.2% and 41.5% of donors, respectively
(Fig. 3c, d). The total insulin content of the cryopreserved
islets (11.1±1.4 ng/islet, n=43) was significantly lower than
what we can observe in freshly isolated islets today (24.3±
2.3 ng/islet, n=56, p<0.001). However, due to a lack of his-
torical data on the insulin content, we do not know whether
this was reduced at the time of isolation or by the cryopreser-
vation process per se.
Although there was a significant linear correlation (r2=
0.91, p<0.001) between glucose sensitivity and KCl sen-
sitivity (Fig. 3e), the duration of cryopreservation did not
correlate (r2=0.03) with the glucose-stimulated insulin se-
cretion (Fig. 3f). This preserved functional capacity is con-
sistent with our assessment of transcript expression profiles
by RNA sequencing (Fig. 3g) and our demonstration of a
similar expression of the exocytotic and ion channel
genes. There is strong correlation (Spearman’s ρ=0.94)
between the transcriptomes of the cryopreserved and the
fresh islets. The two outliers observed in Fig. 3g are
AMY1A and AMY1C, suggesting differences in islet purity
(although this is likely to be due to the hand-picking of
cryopreserved islets prior to the transcriptome analysis).
Partial functioning of cryopreserved islets transplanted
into diabetic mice To ascertain the extent to which long-
term cryopreserved islets can function in an in vivo model,
we transplanted 2,000–4,000 IEQ from five donors (cryopre-
served for 16.6±1.1 years, stimulation index 1.9±0.4, four to
five recipient animals each) under the kidney capsule of STZ-
induced diabetic B6/Rag−/− mice. Transplantation significant-
ly decreased blood glucose levels (n=5 donors, 23 animals,
p<0.05) but did not restore normoglycaemia (Fig. 4a). The
success of engraftment varied between donors, with only one
group achieving glucose levels similar to those of freshly iso-
lated islets (n=5 donors, 11 mice), although this occurred after
a prolonged delay (Fig. 4b). The success of the engraftment
did not correlate with the stimulation index but did correlate
significantly (r2=0.84, p<0.05) with the insulin content of the
donor islets (Fig. 4c). In all cases, however, the transplanted
cryopreserved islets were sufficient to maintain the animal’s
body weight (Fig. 4d). Human insulin was detected in most
recipient mice following fasting and was significantly (r2=
0.73, p<0.001) correlated with improvements in fasting glu-
cose levels (Fig. 4e).
In mice receiving grafts of cryopreserved islets, OGTTs
were performed at week 10 and again 1 week following graft
removal. Although the animals were hyperglycaemic, their
blood glucose excursions were significantly improved by the
graft (n=23, p<0.001; Fig. 4f), and graft removal increased
the area under the glucose curve (n=23, p<0.01) (Fig. 4g).
Since the maximum value of the capillary glucose meter is
33.3 mmol/l, the true blood glucose values post-
nephrectomy are likely to be higher than reported.
Circulating human insulin at 60 min following glucose chal-
lenge, which was detectable in recipient mice pre-nephrecto-
my, was absent following graft removal (Fig. 4h).
Anti-insulin-horseradish peroxidase (HRP)/3,3′-diaminoben-







































































































































































Fig. 4 Long-term cryopreserved human islets are partially functional
in vivo. (a) Sub-capsular grafts of cryopreserved human islets (2,000–
4,000 IEQ) from five separate donors produced a marginal improvement
in blood glucose level in STZ-diabetic B6/Rag−/− mice, which was re-
versed by removal of the graft-bearing kidney (arrow). (b) Glycaemic
responses to grafts from each of five donors are shown, compared with
the effect of freshly isolated human islets (3,000 IEQ; grey line). The
grafts were removed at the time indicated by the arrow. (c) The success
of reversal of diabetes at 9 weeks correlates with the insulin content of the
cryopreserved islet preparations. (d) Body weight was maintained in the
STZ-diabetic B6/Rag−/− mice following the transplantation of cryopre-
served human islets. (e) Human insulin was detectable in fasted STZ-
diabetic B6/Rag−/− recipient mice, and levels correlated negatively with
fasting blood glucose levels. (f–h) Long-term cryopreserved islets im-
proved intraperitoneal glucose tolerance (white circles) and the AUC of
the glucose response in STZ-diabetic B6/Rag−/− mice, as well as produc-
ing human insulin (h). After removal of the engrafted kidney (black
squares), the glucose excursion was elevated and circulating human in-
sulin was not detectable (ND). *p<0.5, **p<0.01 and ***p<0.001 com-
pared with time=0 or the pre-nephrectomy control
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revealed the retention of human insulin in cryopreserved islet
grafts from four out of five donors after 10 weeks. However,
although grafts of freshly isolated islets showed strong insulin-
positive staining (Fig. 5d), the insulin staining of cryopreserved
islet grafts appeared to beweaker (Fig. 5e–h), consistent with the
lower islet insulin content observed above. The total insulin
content of the grafts of cryopreserved islets was 399.1±
119.4 ng/graft (n=12 grafts, five donors). The level of apoptosis
did not differ between the fresh (4.3±1.6%, n=10) and the cryo-
preserved (5.4±2.0%, n=6) grafts.
Discussion
This is the first report of human islet function following ex-
tended cryopreservation in a large cohort of donors and sug-
gests that the potential storage duration of functional islets can
be increased by an order of magnitude. We have assessed
various steps in the stimulus–secretion coupling pathway
and provide data indicating that long-term cryopreservation
provides a source of human islet material for research that
retains many physiologically relevant properties. Access to
human research islets remains a limiting factor in many scien-
tific studies [2], and the inherent difficulties of distribution and
culture time only add further to the value of any human islet
tissue obtained. Biobanking has the potential to overcome
many of these issues, and the successful retention of physio-
logical function in frozen-thawed islets is desirable.
When assessing beta cell function, several critical compo-
nents of stimulus–secretion coupling must be considered.
These include ion channel activity, which underlies the elec-
trical signal produced in response to glucose stimulation, Ca2+
influx and the exocytotic machinery responsible for the re-
lease of insulin granules [38, 39]. Ultimately, glucose-
stimulated insulin secretion and the ability to restore physio-
logical glucose homeostasis are of key significance.
Our patch-clamp studies revealed that key ion conduc-
tances underlying beta cell excitability remain identical to
those observed in freshly isolated beta cells following up to
21 years of cryopreservation. In addition, measurement of the
exocytotic capacity and glucose sensitivity of single beta cells
demonstrates responses that are indistinguishable from those
of freshly isolated beta cells. These findings expand on those















Fig. 5 Human insulin is
detectable in grafts of long-term
cryopreserved human islets after
10 weeks. (a, b) Anti-insulin
HRP/DAB staining of renal
sub-capsular grafts of long-term
cryopreserved human islets. (c)
Insulin (red) and glucagon (green)
immunofluorescence and DAPI
staining (blue) in a section of a
graft of cryopreserved islets
removed after 10 weeks. (d–h)
Insulin immunostaining (red) and
DAPI staining (blue) of grafts of
freshly isolated islets from three
separate donors (d) and long-term
cryopreserved islets from four
separate donors (e–h). The
cryopreserved islets shown were
from donors that reduced the
blood glucose level in recipient
mice to 12.4 (e), 20.4 (f), 26.3 (g)
and 23.4 (h) mmol/l. Scale bar,
100 μm (a) or 200 μm (b–e)
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and exocytosis in human islets cryopreserved for a much
shorter period in a small cohort of donors [25]. Our data indi-
cate that cryopreserved human islets can serve as an appropri-
ate physiological model in at least some cellular mechanistic
studies.
While these underlying cellular processes remain intact,
in vitro insulin secretion and islet insulin content appear to
be more variable in the cryopreserved islets. The mean glu-
cose stimulation index of 1.90±0.24 (n=43) is low compared
with the values we typically observe today with freshly isolat-
ed human islets (9.53±0.92, n=56; range 1.04–33.83). A re-
duction in insulin secretory capacity has frequently been re-
ported following the cryopreservation of human islets [16, 22,
25, 44, 45]. However, given the limited historical data avail-
able to us, we could only make a direct pre- and post-
cryopreservation comparison for five donors (Fig. 3a, b). As
the secretory profiles for these donors were similar before and
after freezing, it is difficult to conclude that cryopreservation
per se caused a reduced secretory response in our study.
Notably, the return to baseline secretion in the perifusion,
which is difficult to achieve in rat islets cryopreserved using
other protocols [10], suggests that these islets were viable.
Finally, the transcriptome profiles of fresh and cryopreserved
islets were similar, including the expression of genes that cor-
relate with the measurements made here: for insulin (INS), Kv
currents (i.e. KCNB1 and KCNB2), Ca2+ currents (i.e. CACN
A1A, CACNA1H and CACNA1D) and exocytosis (i.e.
VAMP2, STX1A, SNAP25, CPLX1 and SYP).
Our transplantation of cryopreserved islets into STZ-
induced diabetic mice revealed that in vivo function varies
and correlates with islet insulin content. As above, however,
because we do not have data on the pre-freezing insulin con-
tent, we cannot say whether cryopreservation itself reduces the
insulin content or whether this was already lower prior to freez-
ing. Overall, the cryopreserved islets performed relatively
poorly in their ability to normalise blood glucose level
in vivo. The maintenance of the recipients’ body weights and
the presence of circulating human insulin, which correlated
inversely with blood glucose level, indicate, however, that
the cryopreserved islets maintained some function in vivo.
This is supported by the OGTTs, which showed that the grafts
were limiting the blood glucose excursion.Most grafts retained
endocrine cell expression for the full 10 weeks. Indeed, graft-
removing nephrectomy completely abolished the plasma insu-
lin and resulted in severe glucose intolerance. Thus, we con-
clude that the cryopreserved human islet grafts retained at least
some function in vivo, but the reversal of diabetes was limited
by the reduced insulin content of these islets.
In summary, we have demonstrated that long-term cryopre-
served islets may be suitable for cellular studies of the mech-
anisms underlying stimulus–secretion coupling in beta cells,
although further work is required to determine the potential
effects of long-term cryopreservation on insulin content that
may limit their in vivo efficacy. The progress of science and
technology is rapid. These human islets were isolated and
cryopreserved in an era when many of today’s modern tech-
niques were undeveloped or prohibitive in terms of cost. In
less than two decades, the research potential of this tissue has
dramatically increased. The ongoing banking of human islets
is therefore important in order to preserve tissue for the eval-
uation of currently unidentified targets and pathways using
advanced technologies, which will facilitate future research.
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